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This journal is ª The Royal Society ofMetallohelices with activity against cisplatin-resistant
cancer cells; does themechanism involve DNA binding?†
Viktor Brabec,*b Suzanne E. Howson,a Rebecca A. Kaner,a Rianne M. Lord,c
Jaroslav Malina,b Roger M. Phillips,d Qasem M. A. Abdallah,d Patrick C. McGowan,c
Alison Rodgera and Peter Scott*a
Enantiomers of a relatively rigid DNA-binding metallo-helix are shown to have comparable activity to that
of cisplatin against the cell lines MCF7 (human breast adenocarcinoma) and A2780 (human ovarian
carcinoma) but are ca ﬁve times more active against the cisplatin-resistant A2780cis. The cell-line
HCT116 p53+/+ (human colon carcinoma) is highly sensitive giving IC50 values in the nM range, far lower
than the cisplatin control. The hypothesis that the biological target of such metallohelices is DNA is
probed by various techniques. Tertiary structure changes in ct-DNA (formation of loops and
intramolecular coiling) on exposure to the compounds are demonstrated by atomic force microscopy
and supported by circular/linear dichroism in solution. Selectivity for 50-CACATA and 50-CACTAT
segments is shown by DNase I footprinting. Various three- and four-way oligonucleotide junctions are
stabilised, and remarkably only the L metallo-helix enantiomer stabilizes T-shaped 3WJs during gel
electrophoresis; this is despite the lack of a known helix binding site. In studies with oligonucleotide
duplexes with bulges it is also shown for the ﬁrst time that the metallo-helix binding strength and the
number of binding sites are dependent on the size of the bulge. In contrast to all the above, ﬂexible
metallo-helices show little propensity for structured or selective DNA binding, and while for A2780 the
cancer cell line cytotoxicity is retained the A2780cis strain shows signiﬁcant resistance. For all
compounds in the study, H2AX FACS assays on HCT116 p53+/+ showed that no signiﬁcant DNA damage
occurs. In contrast, cell cycle analysis shows that the DNA binders arrest cells in the G2/mitosis phase,
and while all compounds cause apoptosis, the DNA binders have the greater eﬀect. Taken together
these screening and mechanistic results are consistent with the more rigid helices acting via a DNA
binding mechanism while the ﬂexible assemblies do not.Introduction
Clinical anticancer treatments commonly include the use of
DNA-binding or -modifying drugs. Alkylators and DNA cleavage
agents cause chemically irreversible reactions leading, in the
absence of repair, to cell death,1,2 whereas DNA groove-binders
and intercalators form non-covalent bonds, commonly aﬀecting
replication and transcription.3,4 Coordination chemistry plays
an important role in both these areas;5,6 cisplatin chemotherapy
is a resurgent eld of research7–9 and metal scaﬀolds are beingarwick, Gibbet Hill Road, Coventry, CV4
; Fax: +44 (0)24 7657 2710; Tel: +44 (0)
iences of the Czech Republic, v.v.i.,
epublic. E-mail: brabec@ibp.cz
oodhouse Lane, Leeds, LS2 9JT, UK
of Bradford, Bradford, BD7 1DP, UK
ESI) available: Experimental details for
CD and LD, DNase I footprinting, UV
g. See DOI: 10.1039/c3sc51731d
Chemistry 2013used to explore regions of biologically relevant chemical space
inaccessible to organic chemistry alone.10–13
One such architecture is provided by metal-templated heli-
cates14–19 (Fig. 1, upper). These molecules commonly comprise
three relatively rigid ditopic ligands such as the NN–NN system
I20 wrapped in a helical array around two metal ions. The ligandFig. 1 Schematic representation (upper) of one enantiomer of a bimetallic
triple-stranded metallo-helicate incorporating a NN–NN bis(bidentate) helicand.
Chem. Sci., 2013, 4, 4407–4416 | 4407
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View Article Online(referred to as a helicand) mechanically couples21 the helicity at
the two metal centres such that they have the same absolute
conguration (D or L). Their structural novelty has encouraged
testing in the healthcare arena e.g. towards diagnostic applica-
tions22–29 but there are rather few metallo-helix systems that
lend themselves to projects in drug discovery.19
Hannon's tetracations [M2(I)3]
4+ (M ¼ Fe, Ru) have been
preeminent because of their simplicity and solubility,30 and
despite their requirement for chromatographic resolution. They
bind in the major groove of DNA with sequence-selectivity,31
induce intramolecular coiling32 and have some anticancer
activity.33–35 Qu has discovered that the same Fe compound
recognises human telomeric G-quadruplex DNA36–38 and targets
the amyloid b peptide, reducing cytotoxicity and ameliorating
memory decits in a transgenic mouse model.39 Recently a
derivative of [Fe2(I)3]
4+ containing arginine units showed
improved cytotoxicity against A2780 ovarian cancer cells.40
We recently developed optically and diastereochemically
pure monometallic complexes containing functionalised pyri-
dine/imine units41,42 and then used them to create via self-
assembly processes water stable, optically pure bimetallic
structures with exible linkers [M2L3]
2+ (Fig. 2).43 Since the
stereoselectivity in these complexes does not rely on the helicate
concept of mechanical coupling we describe them as
exicates,43,‡ although in other instances mechanical coupling
is important.44 We also reported their promising antibiotic
activity against MRSA (Methicillin-resistant Staphylococcus
aureus) and Escherichia coli alongside modest toxicity towards
the nematode worm Caenorhabditis elegans.43 In this work we
describe the discovery of structure-dependent activity of ex-
icates against cancer cell-lines, including a cisplatin-resistant
strain, and address the interactions of these compounds with
potential drug targets in DNA and DNA-motifs via a range of
biophysical techniques relevant to mechanism of action.45 InFig. 2 Diastereomerically pure metallo-helical “ﬂexicate” complexes of chiral
ligands L1 and L2.
4408 | Chem. Sci., 2013, 4, 4407–4416addition we probe the eﬀects on cells via assay of DNA damage
and cell-cycle analysis.
Results and discussion
Cancer cell-line activity
The absence of reactive metal centres in the helicates [M2(I)3]
4+
(Fig. 1) described above means that a cisplatin-like lesion
process is unlikely to be responsible for their cancer cell line
cytotoxicity, yet it has been hypothesised that DNA binding is
involved in the mechanism.33–35 The exicate compounds
[Fe2L3]
4+ (Fig. 2) present an interesting series in this respect;
linear dichroism studies indicate that while [Fe2L
1a
3]
4+ binds to
the major groove of calf thymus DNA, the system [Fe2L
2a
3]
4+
does not. We thus set out to investigate the activity of the water
soluble exicates in cancer cell lines; MCF7 (human breast
adenocarcinoma), A2780 (human ovarian carcinoma), the
cisplatin resistant strain A2780cis and HCT116 p53+/+ (human
colon carcinoma). In preliminary tests it was found that solu-
tions of [Fe2L
1b
3]Cl4 deposited solid complex under assay
conditions and so our studies were conned to the remaining
six compounds (three pairs of enantiomers) containing L1a, L2a
and L2b. The free ligands and major components were insuﬃ-
ciently soluble in DMSO/water for testing.
The exicates show promising anticancer properties with a
range of IC50 values from ca 0.6–20 mM (Table 1). The enantio-
mers containing L1a were generally the most potent, and while a
direct comparison with related helicates33,34 is not easy to make,
reference to the cisplatin control experiments indicates that the
activities here are at least comparable with the more recently
reported arginine derivatives of Hannon.40 The most striking
result however is that exicates based on L1a exhibit potent
cytotoxic eﬀects on the cisplatin-resistant ovarian tumour cell
line A2780cis. The eﬀect is marked; there is an approximate
5-fold diﬀerence between the IC50 values for these exicates and
cisplatin towards A2780cis. Furthermore A2780cis is more
sensitive to these L1a exicates than is the parental line A2780.
The exicates based on L2a/2b are generally less cytotoxic but
the diﬀerences in sensitivity between cell lines (i.e. selectivity) is
marked. In particular A2780cis is resistant to these compounds,
with IC50 values 2–6 times higher than those for the parent cell
line. At the same time, some of the diﬀerences in IC50 between
enantiomers are very signicant with the L-[Fe2L
2a
3]Cl4 isomer
being more potent. Again, this contrasts with the L1a complex
enantiomers where only marginal diﬀerences were observed.Table 1 Anticancer activities of the ﬂexicates
Complex
IC50/mM (esd)
MCF7 A2780 A2780cis HCT116 p53+/+
Cisplatin 1.33 (0.23) 0.93 (0.04) 10.46 (0.15) 3.51 (1.50)
L-[Fe2L
1a
3]Cl4 3.67 (0.14) 4.80 (0.15) 2.18 (0.07) 1.66 (1.05)
D-[Fe2L
1a
3]Cl4 2.95 (0.77) 3.75 (0.10) 2.39 (0.12) 0.61 (0.31)
L-[Fe2L
2a
3]Cl4 5.50 (0.52) 3.29 (0.09) 7.34 (0.32) 0.62 (0.08)
D-[Fe2L
2a
3]Cl4 10.16 (0.18) 3.48 (0.04) 14.39 (0.39) 0.87 (0.13)
L-[Fe2L
2b
3]Cl4 6.08 (0.21) 4.29 (0.08) 12.72 (0.03) 0.64 (0.15)
D-[Fe2L
2b
3]Cl4 8.26 (0.16) 3.10 (0.10) 18.20 (0.15) 0.61 (0.07)
This journal is ª The Royal Society of Chemistry 2013
Fig. 3 AFM images of linear plasmid pSP73 (2464 bp) mixed with ﬂexicates at
various DNA base : ﬂexicate ratios. (A–C) DNA with LFe,SC-[Fe2L
1a
3]Cl4 at 5 : 1,
3 : 1 and 2 : 1 ratios, respectively. (D–F) DNAwith LFe,RC-[Fe2L
2a
3]Cl4 at 1 : 2, 1 : 4
and 1 : 6 ratios, respectively.
Fig. 4 CD titration series for DFe/LFe-[Fe2L
1a
3]Cl4 at constant ﬂexicate concen-
trations (15 mM) and increasing ct-DNA concentrations (indicated in legend).
TRIZMA base buﬀer (1 mM, pH 7.2). Path length 1.0 cm.
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View Article OnlineThe HCT116 p53+/+ cell line is sensitive to all the exicates
and IC50 values in the nM range are observed, signicantly
lower than the cisplatin control.
Across the panel there are large diﬀerences in sensitivity to
individual compounds e.g. a factor of ca 30 in sensitivity between
the highest and lowest IC50 observations for D-[Fe2L
2b
3]Cl4.
Given the range of IC50 values in Table 1 and the ready
availability and stability in water of enantiomers of the test
compounds we have been able to address in more detail the
relationship between the binding of various DNA motifs and
cytotoxicity.
Atomic force microscopy
The inuence of the exicates on the tertiary structure of single
DNA molecules was studied by direct visualisation of linearized
plasmid pSP73 (2464 bp) mixed with increasing concentrations
of the exicates using atomic force microscopy (AFM) tapping
mode in air. Samples for imaging were prepared by adsorption
of the exicates onto freshly cleaved mica in the presence of
5 mM Mg(II). The non-modied linearized plasmid molecules
appeared as relaxed and well-separated strands; crossing
strands were rarely observed [see ESI, Fig. S1(a and b)†]. The
addition of [Fe2L
1a
3]Cl4 and [Fe2L
2a
3]Cl4 exicates aﬀected the
conformation of linear plasmid DNA yielding typical images as
shown in Fig. 3.
For [Fe2L
1a
3]Cl4, an increase in formation of loops and close
strand contacts was seen for both enantiomers at lower DNA
base : exicate ratios up to 5 : 1 (shown for L-enantiomer in
Fig. 3(A)). On increasing the concentration of exicates (Fig. 3(B
and C)) intramolecular coiling and intermolecular aggregation
of DNAmolecules wasmore pronounced. A level of cooperativity
in the coiling process was apparent, since clusters and fully
coiled DNA strands were observed in the presence of uncoiled
DNA molecules. The extent of coiling and aggregation was
slightly higher for the L enantiomer than the D enantiomer.
The eﬀects of the [Fe2L
1a
3]Cl4 exicates on DNA coiling diﬀer
from that reported for the [Fe2(I)3]Cl4 helicate32 which induced
almost exclusively intramolecular coiling of individual DNA
molecules and did not exhibit a tendency to condense DNA into
intermolecular clusters [see ESI, Fig. S1(c)†].
Typical AFM images of linear DNA mixed with [Fe2L
2a
3]Cl4
are shown in Fig. 3(D–F) and indicate diﬀerent behaviour from
[Fe2L
1a
3]Cl4. No intramolecular coiling was observed even at
high loadings of [Fe2L
2a
3]Cl4 (Fig. 3(F)). Thick-stranded features
made by tight coiling of two individual DNA strands and some
intermolecular aggregates were predominantly seen (Fig. 3(E
and F)). To observe a similar level of DNA condensation as seen
with the [Fe2L
1a
3]Cl4 exicates, the concentration of [Fe2L
2a
3]Cl4
was required to be approximately 10–20-fold higher. No diﬀer-
ence between enantiomers was noticed. These observations are
entirely consistent with the [Fe2L
2a
3]Cl4 exicates only showing
weak electrostatic binding to DNA.
DNA binding studies using spectroscopic methods
Circular dichroism titration experiments were used to investi-
gate the binding of the water soluble [Fe2L3]Cl4 exicateThis journal is ª The Royal Society of Chemistry 2013enantiomers to calf-thymus DNA (ct-DNA) as shown in Fig. 4
and in ESI.† Changes to peaks below 300 nm are predominantly
due to the intrinsic ct-DNA CD signals that occur in this region.
In the MLCT region, i.e. that of the intense bisignate curvesChem. Sci., 2013, 4, 4407–4416 | 4409
Fig. 5 Comparison of the reduction in the linear dichroism absorption of the ct-
DNA 260 nm peak in the presence of various complexes. DNA base : complex
ratio 7 : 1 throughout. Values for DFe/LFe-[Fe2L
1a
3]Cl4 ﬂexicates are calculated
using ﬁlm LD and UV-Vis absorbance data. Data from Hannon and co-workers
taken from previously reported work.32,47
Fig. 6 Autoradiogram of DNase I footprint of 30 end labeled top strand of the
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View Article Onlinebetween 450 and 650 nm, subtle changes in the intensity and
wavelength are consistent with distortion of the complex in the
region of the Fe(pyridine/imine)3 chromophore on binding to
the DNA. The DFe,RC-[Fe2L
1a
3]Cl4 exicate shows the largest
change of the tested complexes. The changes in the CD of the
correspondingL isomer of L1a (Fig. 4) as well as of the exicates
based on L2a and L2b (see ESI, Fig. S2 and S3†) are much smaller
and therefore suggest smaller distortions to the geometries of
the complexes on binding to DNA. Perturbations of charge-
transfer absorptions were also observed in ct-DNA/[Fe2(I)3]
4+
solutions.46
The extent to which these interactions cause disruption in
the DNA structure in solution may be estimated from the
reduction in the intensity of the DNA linear dichroism (LD)
absorption at ca 260 nm. Suitable linear dichroism (LD) spectra
(Fig. S4–S9) and details of calculation of the peak intensity are
given in ESI.† The data are summarised in Fig. 5. This reduction
in intensity almost certainly comes from bending or coiling, as
we have seen in the solid state by AFM, that reduces alignment
of the DNA with the laminar ow in the cell. It is rather less
likely to result from an increase in the exibility of the DNA. The
percentage reduction in the DNA peak follows the trend L1a >
L2a > L2b. The LFe compounds cause more disruption to the
DNA structure, indicating stronger preferences for binding
with the LFe enantiomer in each case. In comparison to the
iron(II) exicates reported here, [Fe2(I)3]
4+ causes a higher
degree of disruption to the DNA structure at the same DNA
base : complex ratio32,47 and this correlates well with AFM data.158 bp HindIII/NdeI restriction fragment of the plasmid pSP73 in the presence of
the ﬂexicates. The nucleotide sequence of the fragment is shown on the right side
of the gel and numbers refer to the sequence shown in the corresponding
diﬀerential cleavage plots in Fig. 8. For (a) lane 1: DNA in the absence of ﬂexicates,
lanes 2–7: DNA mixed with LFe,SC-[Fe2L
1a
3]Cl4, DFe,RC-[Fe2L
1a
3]Cl4, LFe,RC-
[Fe2L
2a
3]Cl4, DFe,SC-[Fe2L
2a
3]Cl4, LFe,SC-[Fe2L
2b
3]Cl4, DFe,RC-[Fe2L
2b
3]Cl4 respec-
tively. All at 10 : 1 (DNA base : ﬂexicate) ratios. For (b) lane 1: DNA in the absence
of ﬂexicates, lanes 2 and 3: DNA mixed with LFe,SC-[Fe2L
1a
3]Cl4 at 20 : 1 and
10 : 1 (DNA base : ﬂexicate) ratios respectively, lanes 4 and 5: DNA mixed with
DFe,RC-[Fe2L
1a
3]Cl4 at 20 : 1 and 10 : 1 ratios respectively, lanes G + A and G
correspond to Maxam–Gilbert G + A and G ladders.DNase I footprinting
In order to obtain information on sequence-specicity in the
binding events that appear to lead to the tertiary structure
changes described above, footprinting methodology was used.
Deoxyribonuclease I (DNase I) is the most commonly used
nuclease for these experiments and the reaction conditions
used were such that, on average, each DNA strand was cut once4410 | Chem. Sci., 2013, 4, 4407–4416giving a mixture of diﬀerent fragments. A compound bound to
DNA protects the DNA from cleavage at their binding sites.
Each exicate was mixed with the 158 bp HindIII/NdeI
restriction fragment of pSP73 followed by partial cleavage by
DNase I. The autoradiograms of the DNA cleavage inhibition
patterns are shown in Fig. 6. Comparing the patterns observed
in the presence and absence of the exicates shows some
evidence of footprints in the gel particularly for the LFe,SC-
[Fe2L
1a
3]Cl4 exicate around positions 50 and 70 (Fig. 6(a), lane
2 and Fig. 6(b), lanes 2, 3) indicating specic sequences in DNA
are recognised. There are only minor diﬀerences between the
autoradiograms for the exicates at 20 : 1 and 10 : 1 (DNA
base : exicate) ratios (Fig. 6(b)).This journal is ª The Royal Society of Chemistry 2013
Fig. 8 The sequences of the oligonucleotides used to form (a) Y-shaped 3WJ,
and T-shaped 3WJs containing two unpaired (b) adenosines 3WJ-AA or (c)
thymidines 3WJ-TT at the branch point of the junction.
Table 2 Eﬀect of ﬂexicates on thermal stability of Y- and T-shaped 3WJs at 1 : 1
and 2 : 1 (ﬂexicate : 3WJ) ratios
Complex
Y-shaped
3WJ DTm (C)
T-shaped
3WJ-AA DTm
(C)
T-shaped
3WJ-TT DTm
(C)
1 : 1 2 : 1 1 : 1 2 : 1 1 : 1 2 : 1
L-[Fe2L
1a
3]Cl4 20.1 20.3 8.3 9.4 9.6 10.7
D-[Fe2L
1a
3]Cl4 18.2 18.5 7.0 8.1 9.6 10.7
L-[Fe2L
2a
3]Cl4 9.0 10.4 0.2 0.4 2.8 3.6
D-[Fe2L
2a
3]3Cl4 13.1 12.6 1.7 2.5 5.4 6.2
L-[Fe2L
2b
3]Cl4 7.1 8.9 0.5 0.8 2.6 3.5
D-[Fe2L
2b
3]Cl4 11.0 11.8 1.6 2.4 5.1 6.2
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View Article OnlineFurther information on the binding specicity of the
[Fe2L
1a
3]Cl4 enantiomers was obtained from the intensities of
the bands from the gel lanes in Fig. 6. For bands containing
DNA mixed with the [Fe2L
1a
3]Cl4 enantiomers at 10 : 1 (DNA
base : exicate) ratios were measured by densitometry and the
resulting diﬀerential cleavage plots are shown in Fig. 7. Nega-
tive values indicate inhibition of DNase I cleavage at that
section whereas positive values indicate enhancement. It can be
seen that DFe,RC-[Fe2L
1a
3]Cl4 does not display signicant
patterns of protection and enhancement. Conversely, the
diﬀerential cleavage plot for LFe,SC-[Fe2L
1a
3]Cl4 contains two
major regions where the exicate has protected the DNA from
DNase I cleavage. These sites are centred around positions 52
and 70 and extend over approximately 5–6 bp. Applying a shi
of 2–3 bp in the 30 direction is necessary to correct for the fact
that DNase I binds across the minor groove.48,49 From this
assumption, the two preferential binding sites of LFe,SC-
[Fe2L
1a
3]Cl4 can be deduced as 50-CACATA and 50-CACTAT
starting at positions 51 and 69, respectively. Hence there appear
to be fewer preferential binding sites than has been
observed31,50 for [Fe2(I)3]
4+ and [Ru2(I)3]
4+.
Supramolecular interactions of exicates with oligonucleotide
motifs
In this section we investigate the possibility of exicate inter-
actions with other potential drug target DNA structures relevant
to DNA replication and recombination.
Three-way junctions
Three-way junctions (3WJs) consist of three double strands
converging at one point (Fig. 8).51 Typically found in both DNA
(e.g. replication forks)52 and RNA,53 they are potential drug
targets. Fig. 8(a) shows a Y-shaped 3WJ (Tm ¼ 35.0 C) of the
type shown to bind one particular helicate molecule in the
central cavity.54 T-shaped 3WJs, which do not in their relaxed
state have such a cavity are found where unpaired bases appear
in the junction region;51 the systems of Fig. 8(b and c) have two
unpaired adenosines (3WJ-AA) and two unpaired thymidines
(3WJ-TT) and higher melting temperatures of 41.4 C andFig. 7 Caption diﬀerential cleavage plots for theLFe- and DFe-enantiomers of [Fe2L
1
158 bp HindIII/NdeI restriction fragment of the plasmid pSP73 at 10 : 1 (DNA base : ﬂ
cleavage at any bond in the presence of ﬂexicate and f0 is the fractional cleavage of th
indicate inhibition.
This journal is ª The Royal Society of Chemistry 201338.5 C respectively. As shown in Table 2, addition of exicates
to solutions of all of these oligonucleotide assemblies increases
the melting temperatures (Tm) i.e. increases thermal stability.
The L1a exicates are consistently more eﬃcient at stabilis-
ing the 3WJs than are the L2 exicates. In all cases, doubling the
ratio from 1 : 1 to 2 : 1 (exicate : 3WJ) had almost no further
eﬀect on the stability suggesting all the 3WJs contain just one
major binding site.
Gel electrophoresis was used to gainmore information about
the stabilisation eﬀect that the exicates bring to DNA 3WJs.55
The three 14 base single strand oligonucleotides used in the
Y-shaped 3WJ of Fig. 8(a) provide the minimum length required
for the assembly to persist during electrophoresis at low
temperatures (5 C) in the presence of magnesium(II) ions.56a
3]Cl4 showing the induced diﬀerences in susceptibility to DNase I digestion on the
exicate) ratio. The vertical scale is in units of ln(fc) ln(f0), where fc is the fractional
e same bond in the control. Positive values indicate enhancement, negative values
Chem. Sci., 2013, 4, 4407–4416 | 4411
Fig. 10 Autoradiograms of the gels run at room temperature. Lane C1: control
containing the three strands, S1-AA, S2 and S3. Lanes 1–3: S1-AA, S2 and S3
mixed with LFe,SC-[Fe2L
1a
3]Cl4 at 0.5 : 1, 1 : 1 and 2 : 1 (ﬂexicate : 3WJ) ratios,
respectively. Lanes 4–6: S1-AA, S2 and S3mixed with DFe,RC-[Fe2L
1a
3]Cl4 at 0.5 : 1,
1 : 1 and 2 : 1 (ﬂexicate : 3WJ) ratios, respectively. Lane C2: control containing the
three strands, S1-TT, S2 and S3. Lanes 7–9: S1-TT, S2 and S3 mixed with LFe,SC-
[Fe2L
1a
3]Cl4 at 0.5 : 1, 1 : 1 and 2 : 1 (ﬂexicate : 3WJ) ratios, respectively. Lanes
4–6: S1-TT, S2 and S3 mixed with DFe,RC-[Fe2L
1a
3]Cl4 at 0.5 : 1, 1 : 1 and 2 : 1
(ﬂexicate : 3WJ) ratios, respectively.
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View Article OnlineWithout Mg2+ ions present, these 3WJs split into single strands
[Fig. 9(a) lane C]. Fig. 9(a) shows that both [Fe2L
1a
3]
4+ enantio-
mers (lanes 1–6) are able to stabilise the Y-shaped 3WJ during
electrophoresis in the absence of Mg2+ at room temperature.
The L2 exicates, DFe/LFe-[Fe2L
2a
3]Cl4 (lanes 7, 8) and DFe/LFe-
[Fe2L
2b
3]Cl4 (lanes 9, 10), had no or very little eﬀect on the
stability of this 3WJ under these conditions. Consistent with the
melting experiments above, a plot of the percentage of 3WJs
remaining aer electrophoresis as a function of exicate
concentration [Fig. 9(b)] clearly shows that for [Fe2L
1a
3]Cl4, the
LFe enantiomer stabilises the Y-shaped 3WJ during electro-
phoresis to a greater extent compared with the DFe enantiomer
(Fig. 10).
The related gel electrophoresis experiments on the T-shaped
3WJs of Fig. 8(b and c)] show an extraordinary diﬀerence in the
behaviour of enantiomers DFe/LFe-[Fe2L
1a
3]Cl4; with both 3WJ-
AA and 3WJ-TT, stabilisation was only observed with the LFe
enantiomer (lanes 1–3 and 7–9).
The mechanisms of binding to Y- and T-shaped 3WJ must
thus diﬀer. With the Y-shaped 3WJ, it is likely that the exicates
bind to the central hollow cavity at the branch point of the
junction;54 notably the DTm are consistently higher for these
“preorganised” systems. In contrast for the T-shaped 3WJs we
propose the structure of the junction may be being changed on
binding to accommodate the exicate; something that may
explain the enhanced enantioselectivity.Fig. 9 (a) Autoradiogram of the gel run at room temperature. Lane ss: control
containing a single strand. Lane C: control containing all three strands S1, S2 and
S3. Lane 1–3: S1, S2 and S3mixed withLFe,SC-[Fe2L
1a
3]Cl4 at 0.5 : 1, 1 : 1 and 2 : 1
(ﬂexicate : 3WJ) ratios, respectively. Lanes 4–6: S1, S2 and S3 mixed with
DFe,RC-[Fe2L
1a
3]Cl4 at 0.5 : 1, 1 : 1 and 2 : 1 (ﬂexicate : 3WJ) ratios, respectively.
Lanes 7–10: S1, S2 and S3 mixed with LFe,RC-[Fe2L
2a
3]Cl4 (7), DFe,SC-[Fe2L
2a
3]Cl4
(8), LFe,SC-[Fe2L
2b
3]Cl4 (9) and DFe,RC-[Fe2L
2b
3]Cl4 (10) at 1 : 1 (ﬂexicate : 3WJ)
ratio. (b) Plot of the % of 3WJs remaining after electrophoresis as a function of
ﬂexicate concentration.
4412 | Chem. Sci., 2013, 4, 4407–4416We note that while only L isomer of [Fe2L
1a
3]Cl4 stabilizes
T-shaped 3WJ-TT during gel electrophoresis, both L and D
compounds increase the melting temperatures equally. A plau-
sible explanation might be while the gel electrophoresis in the
absence of Mg2+ was carried out at room temperature (22 C) and
observes the proportion of 3WJs remaining aer electrophoresis,
the melting temperatures (40 C) rather reect the properties of
the 3WJs at the elevated temperatures when 3WJs start to melt.
Thus, melting temperatures may not reect relatively small
diﬀerences in the capability of the two isomers to stabilize
T-shaped 3WJs-TTwhereas the gel electrophoresis apparently can.
Four-way junctions
Four-way junctions (4WJs), e.g. the Holliday junction,57 consist
of four double strands converging at one point and are also
potential DNA drug targets.58 The thermal stability of the 4WJ
shown in Fig. 11 (Tm ¼ 42.4 C) in the presence of the exicates
was investigated. The L2 systems (DFe/LFe-[Fe2L
2a
3]Cl4 and DFe/
LFe-[Fe2L
2b
3]Cl4) had small or even a negative eﬀect on the
stability of this 4WJ (Table 3). The melting temperature was,
however, found to increase in the presence of both enantiomers
of the [Fe2L
1a
3]Cl4 exicates with the LFe enantiomer providing
some additional stability in comparison to the DFe enantiomer.
Additionally it was found that the increase in melting temper-
ature of this 4WJ as the concentration of the L1a exicates
increases above the stoichiometric ratio suggests that, unlike
the 3WJs, the 4WJ contains more than one binding site for these
complexes.Fig. 11 The sequences of the oligonucleotides used to form the 4WJ.
This journal is ª The Royal Society of Chemistry 2013
Table 3 Eﬀect of ﬂexicates on thermal stability of a 4WJ (Tm ¼ 42.4 C) at 1 : 1
and 2 : 1 (ﬂexicate : 4WJ) ratios
Flexicate
DTm (C)
of 4WJ at 1 : 1
DTm (C)
of 4WJ at 2 : 1
L-[Fe2L
1a
3]Cl4 6.7 9.7
D-[Fe2L
1a
3]Cl4 5.8 6.5
L-[Fe2L
2a
3]Cl4 1.5 1.5
D-[Fe2L
2a
3]Cl4 1.4 1.4
L-[Fe2L
2b
3]Cl4 0.0 0.2
D-[Fe2L
2b
3]Cl4 0.5 1.0
Table 4 Eﬀect of the ﬂexicates on the thermal stability of duplexes with triple-,
double-, single- and no-adenine bulges at 1 : 1 and 2 : 1 (ﬂexicate : duplex)
ratiosa
Complex
A3 bulge
DTm (C)
A2 bulge
DTm (C)
A1 bulge
DTm (C)
No bulge
DTm (C)
1 : 1 2 : 1 1 : 1 2 : 1 1 : 1 2 : 1 1 : 1 2 : 1
L-[Fe2L
1a
3]Cl4 8.2 10.2 4.6 5.5 3.6 6.9 1.2 2.4
D-[Fe2L
1a
3]Cl4 8.8 10.3 4.2 5.5 1.4 2.5 0.0 0.0
L-[Fe2L
2a
3]Cl4 0.2 0.1 0.1 0.1 0.3 0.7 — —
D-[Fe2L
2a
3]3Cl4 0.1 0.2 0.1 0.1 0.1 0.1 — —
L-[Fe2L
2b
3]Cl4 0.0 0.1 — — — — — —
D-[Fe2L
2b
3]Cl4 0.2 0.1 — — — — — —
a Tm for only one set of exo-imine exicates with A2 and Al bulges were
measured due to their similarly low stabilising eﬀects with the A3 bulge.
As stabilisation was only observed with DFe/LFe-[Fe2L
1a
3]Cl4, Tm for the
no-bulge control was measured for these exicates only.
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View Article OnlineOligonucleotide duplexes with bulges
Oligonucleotide duplexes with bulges occur when one or more
of the bases on one of the strands have no base(s) on the
complementary strand to form a base-pair with. Bulge sites in
DNA have been shown to bind some proteins more strongly
than standard duplex DNA59 and therefore are of signicant
interest as targets for novel drugs,60,61 particularly in the context
of peptidomimetic helices. The thermal stabilities of the
oligonucleotide duplexes containing three-, two- and one-
adenine bulges (A3–A1) [Fig. 12(a–c)] in the presence of
the exicates were analysed. The melting temperature of
the duplexes depends on the size of the bulge, increasing from
35.2 C (A3) to 38.7 C (A2) to 45.0 C (A1) as the number of
unpaired adenines in the bulge decreases. The same duplex
without a bulge was also investigated as a control and has a
melting temperature 54.9 C. The results are listed in Table 4
and show that only the DFe/LFe-[Fe2L
1a
3]Cl4 exicates have
positive impacts on the thermal stability.
With the duplexes containing A3 and A2 bulges, the stabil-
ising eﬀect of the exicates decreases with the size of the bulge.
The thermal stability of these duplexes is further increased
when the exicate : duplex ratio is increased from 1 : 1 to 2 : 1,
but the increase is only relatively small (1–2). This is consistent
with a single dominant binding site for the exicates on these
bulges with up-take slightly higher at the increased 2 : 1
concentration. In addition, there are no signicant diﬀerences
between enantiomers.
The eﬀect of DFe/LFe-[Fe2L
1a
3]Cl4 on the thermal stability
of the duplex containing the A1 bulge shows diﬀerent trends.
At a 1 : 1 exicate : duplex ratio the increase in meltingFig. 12 (a–c) The sequences of the oligonucleotide duplexes containing a three-,
two- and one-adenine bulge, respectively. (d) The corresponding duplex used as a
control.
This journal is ª The Royal Society of Chemistry 2013temperature is relatively small, however on increasing this
ratio to 2 : 1 the DTm approximately doubles, suggesting at
least two binding sites are present per duplex. This indicates
a diﬀerent binding mode of DFe/LFe-[Fe2L
1a
3]Cl4 to the A1
bulge than to the A2 and A3 bulges. Furthermore, enantio-
meric diﬀerences are observed with the A1 bulge. The LFe
enantiomer has the greater stabilising eﬀect on the A1 bulge,
with DTm more than twice that observed for the DFe
enantiomer.H2AX expression analysis
We noted earlier that in contrast to DNA cleavage agents and
“alkylators” (including cisplatin), groove-binders reversibly
form non-covalent bonds such as those indicated in the above
studies, so it is of interest in terms of the mechanism of action
in cells to study the extent of DNA damage. H2AX is a histone
which plays a key role in the repair of damaged DNA62–65 and its
expression is a useful marker for several types of DNA damage.66
We selected the cell line HCT116 p53+/+ for this study since it is
sensitive to all the exicates.
HCT116 p53+/+ cells (5  105 cells in 10 ml RPMI medium)
were incubated with 10 mM of each exicate for 24 h (a dose that
kills 55 to 72% of cells) under appropriate conditions (see ESI†).
These, along with a control of untreated HCT116 p53+/+ cells
were analysed using uorescence-activated cell sorting (FACS).
Fig. 13 shows that there are no signicant alterations in the
production of H2AX, indicating that no DNA damage (increase
in expression) or interruption of the H2AX pathway (decrease)
has occurred.Cell cycle analysis
We further investigated mechanism of action of exicates by
assessing how they aﬀect the population of phases of the cell
cycle for HCT116 p53+/+. Using standard methods the cells
were permeabilised and treated with the uorescent dye
propidium iodide (PI) which stains DNA quantitatively. The
proportion of cells in the various phases – sub G1Chem. Sci., 2013, 4, 4407–4416 | 4413
Fig. 13 H2AX expression of HCT116 p53+/+ cells after treatment with ﬂexicates
(10 mM) for 24 h, and untreated cells (control).
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View Article Online(apoptotic67), G1 (increase in size in readiness for DNA repli-
cation), S (DNA synthesis), G2 (preparation for mitosis) and
M (mitosis) – were determined by uorescence via FACS
analysis as a result of the diﬀering amounts of DNA in the
cells (see ESI†).
As can be seen in Fig. 14, [Fe2L
1a
3]Cl4 exicates show a
dramatic increase in the proportion of cells in G2/M phase
compared to the control (from ca 20 to 40% of cells); such
arresting of cell growth at this phase is likely to be a signi-
cant factor in the mechanism of action. As in the cell-free DNA
binding studies, the LFe enantiomer has the strongest eﬀect
of all compounds tested. Interestingly [Fe2L
2a–b
3]Cl4 exicates
did not show a signicant increase in the G2/M phase, indi-
cating a diﬀerent mechanism. Fig. 14 also shows a very
pronounced increase in population of sub G1 cells, from 4%
in the control to between 13 and 30%, the latter being again
for LFe-[Fe2L
1a
3]Cl4. Cells in the sub G1 phase are considered
apoptotic67,68 and this data is thus consistent with exicates
inducing programmed cell death. Apoptosis induced by
[Fe2L
2a–b
3]Cl4 exicates varies little between enantiomers; this
is consistent with the chemosensitivity data reported in this
cell line.Fig. 14 Cell cycle analysis of HCT116 p53+/+ cells after treatment with ﬂexicates
(10 mM) for 24 h, and untreated cells (control).
4414 | Chem. Sci., 2013, 4, 4407–4416Conclusions
We have shown that while the exicate enantiomers based on
L1a have comparable activity to cisplatin against MCF7 (human
breast adenocarcinoma) and A2780 (human ovarian carcinoma)
they are ca ve times more potent than cisplatin against
A2780cis. For L2a/b complexes the trend is reversed and A2780cis
is rather resistant to L2a/b. The human colon carcinoma cell line
HCT116 p53+/+ is very sensitive to all the compounds, giving
IC50 values in the nM range, substantially more potent than
cisplatin. For some exicates the range of sensitivity is an order
of magnitude or greater, indicating very promising selectively.
The L1a exicates are very good DNA binders and induce
tertiary structural changes of the DNA as seen by AFM and
correlated with solution spectroscopic techniques. The location
of binding in the major groove is supported by the observation
of nucleotide sequence selectivity according to DNase I foot-
printing. The overall picture is that the degree of DNA distortion
falls in the order L1a > L2a > L2b. Given the very similar dimen-
sions of all the complexes we suggest that this may be a function
of exibility; the linker units in L1a are much more rigid than
those in L2a/b. Also, while the L1a complexes cause formation of
loops and close strand contacts, with intramolecular coiling
and intermolecular aggregation at higher loading the L2a
complexes require substantially higher concentrations before
tight coiling of two individual DNA strands was observed.
Binding of the exicates to various other chemotherapeutic
drug targets (3WJs, 4WJs and oligonucleotide duplexes with
bulges) also follows the trend L1a[ L2a > L2b. Fascinatingly,
only the L isomer of [Fe2L
1a
3]Cl4 stabilised T-shaped 3WJs
during gel electrophoresis indicating the importance of our
approach to creating optically pure and non-racemising
systems. We have also shown for the rst time that the inter-
actions (binding strength and number of binding sites) of
metallo-helices with oligonucleotide duplexes with bulges are
dependent on the size of the bulge. This suggests that diﬀerent
sized bulges may be targeted by changing exicate dimensions;
something that is almost uniquely available from our approach
to metallo-helix design. It is possible for example to design
more or less exible, longer or fatter, or diﬀerently functional-
ised analogues; this will feature in future reports aimed at
further probing the existing correlation between metallohelix–
DNA interactions and cytotoxic action.
The H2AX expression data for all compounds in the study
indicate that if reversible DNA major groove binding is involved
in the mode of action, it does not cause DNA lesions; the che-
mosensitivity is not caused by DNA damage. The cell cycle
analysis in HCT116 p53+/+ cells nevertheless shows dramatic
changes in cell-cycle population and that the compounds,
particularly the strongest DNA binders, induce apoptosis.
Taken together, the trends in the cytotoxicity data, the
dramatically diﬀerent abilities to bind DNA motifs and the cell
cycle analysis suggest that the biological targets of [Fe2L
1a
3]Cl4
and [Fe2L
2a/b
3]Cl4 are diﬀerent. The potency of [Fe2L
1a
3]Cl4
against cisplatin resistant A2780cis and its ability to strongly
and selectively bind DNA suggests the involvement of such
an event in the mechanism. We also note that the exibleThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlinesystems L2a/b are based on a pyridine analogue of the antimi-
crobial/antiparasitic agent pentamidine,69 which is a potent
minor groove binder70 and has been proposed as an antitumor
drug.71 The data here do not exclude the possibility that the
assemblies [Fe2L
2a/b
3]
4+ are acting as vectors for delivery of a
ligand L2 or ligand fragments that otherwise have insuﬃcient
solubility for cancer cell-line testing. Nevertheless, we know that
the mechanism of action of [Fe2L
2a/b
3]
4+ does not involve DNA
binding or signicant DNA damage, and the observed diﬀer-
ences in chemosensitivity for particularly the L2a compounds
probably does not arise from diﬀerential DNA binding ability.
These anticancer and preliminary mechanistic results
provide a case for further investigating derivatives, both as
a-helix mimetic groove binders and pro-drugs, depending on
the detail of the metallo-helix design.Acknowledgements
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